Targovax $TRVX.OL clinical phase oncolytic virus valued 35 mUSDTargovax OSL:TRVX a clinical phase norwegian Biotech is currently at market cap NOK 327 million / 35 million USD.
Value inflection point very close as the company will need to raise funds in the very near future, which must either come from investors or from a possible partner deal.
PRESENTATION OF ONCOS-102 MELANOMA DATA AT SITC ANNUAL MEETING
www.healthcap.eu
Q3 report:
www.targovax.com
Q3 transcript:
finance.yahoo.com
